These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 3202864)
1. Lovastatin is hypertriglyceridemic in Syrian golden hamsters. Amin D; Gustafson S; Perrone MH Biochem Biophys Res Commun; 1988 Dec; 157(2):530-4. PubMed ID: 3202864 [TBL] [Abstract][Full Text] [Related]
2. Plant-derived monoterpenes suppress hamster kidney cell 3-hydroxy-3-methylglutaryl coenzyme a reductase synthesis at the post-transcriptional level. Peffley DM; Gayen AK J Nutr; 2003 Jan; 133(1):38-44. PubMed ID: 12514264 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. Kasim SE; LeBoeuf RC; Khilnani S; Tallapaka L; Dayananda D; Jen KL J Lipid Res; 1992 Jan; 33(1):1-7. PubMed ID: 1552226 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level. Peffley DM; Gayen AK Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820 [TBL] [Abstract][Full Text] [Related]
5. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMG-coenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate. Oms P; Assie N; Bruniquel F; Degryse AD; van Haverbeke G; Delhon A Pharmacol Toxicol; 1995 Dec; 77(6):391-6. PubMed ID: 8835365 [TBL] [Abstract][Full Text] [Related]
6. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens. Kalinowski SS; Tanaka RD; Mosley ST Exp Eye Res; 1991 Aug; 53(2):179-86. PubMed ID: 1915674 [TBL] [Abstract][Full Text] [Related]
8. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381 [TBL] [Abstract][Full Text] [Related]
9. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
10. Lovastatin inhibits diet induced atherosclerosis in F1B golden Syrian hamsters. Otto J; Ordovas JM; Smith D; van Dongen D; Nicolosi RJ; Schaefer EJ Atherosclerosis; 1995 Apr; 114(1):19-28. PubMed ID: 7605373 [TBL] [Abstract][Full Text] [Related]
11. Increased cellular triglyceride levels in human monocytic and rat smooth muscle cells after lovastatin. Hrboticky N; Becker A; Kruse HJ; Weber PC Biochim Biophys Acta; 1997 Nov; 1349(3):211-21. PubMed ID: 9434135 [TBL] [Abstract][Full Text] [Related]
12. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Keller RK; Zhao Z; Chambers C; Ness GC Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011 [TBL] [Abstract][Full Text] [Related]
13. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. Kornbrust DJ; MacDonald JS; Peter CP; Duchai DM; Stubbs RJ; Germershausen JI; Alberts AW J Pharmacol Exp Ther; 1989 Feb; 248(2):498-505. PubMed ID: 2918466 [TBL] [Abstract][Full Text] [Related]
14. Effects of dietary cholesterol on hepatic metabolism of free fatty acid and secretion of VLDL in the hamster. Fungwe TV; Cagen LM; Wilcox HG; Heimberg M Biochem Biophys Res Commun; 1994 May; 200(3):1505-11. PubMed ID: 8185606 [TBL] [Abstract][Full Text] [Related]
15. Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes. Elfakhani M; Torabi S; Hussein D; Mills N; Verbeck GF; Mo H Exp Biol Med (Maywood); 2014 Mar; 239(3):293-301. PubMed ID: 24477821 [TBL] [Abstract][Full Text] [Related]
16. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Bassa BV; Roh DD; Vaziri ND; Kirschenbaum MA; Kamanna VS Biochim Biophys Acta; 1999 Mar; 1449(2):137-49. PubMed ID: 10082972 [TBL] [Abstract][Full Text] [Related]
18. Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells. Kam NT; Albright E; Mathur S; Field FJ Biochem J; 1990 Dec; 272(2):427-33. PubMed ID: 2268271 [TBL] [Abstract][Full Text] [Related]
19. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Qin W; Infante J; Wang SR; Infante R Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634 [TBL] [Abstract][Full Text] [Related]
20. The length of 5'-untranslated leader sequences influences distribution of 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in polysomes: effects of lovastatin, oxysterols, and mevalonate. Gayen AK; Peffley DM Arch Biochem Biophys; 1995 Oct; 322(2):475-85. PubMed ID: 7574724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]